Development of Improved Tumor-Residualizing, GRPR-Targeted Agents: Preclinical Comparison of an Endolysosomal Trapping Approach in Agonist and Antagonistic Constructs.
Receptor-targeted radiopharmaceuticals based on low molecular weight carriers offer many clinically advantageous attributes relative to macromolecules, but have generally been hampered by their rapid clearance from tumors thus diminishing tumor to non-target tissue (T/NT) ratios. Herein, we present a strategy using irreversible inhibitors (E-64 derivative) of cysteine cathepsins (CCs) as trapping agents to increase the tumor retention of receptor-targeted agents. Methods: We incorporate these CC trapping agents into agonistic and antagonistic pharmacophores targeting the gastrin-releasing peptide receptor (GRPR). The synthesized radioconjugates with either an incorporated CC inhibitor or matching control were examined using in vitro and in vivo models employing the GRPR-positive, PC-3 human prostate cancer cell line. Results: From the in vitro studies, it was confirmed by multiple techniques that the CC trapping, GRPR-targeted constructs were able to increase cellular retention by forming intracellular macromolecules adducts. Using PC-3 tumor-bearing xenograft mice, it was observed that the CC trapping, GRPR-targeted agonistic and antagonistic constructs led to an approximately 2-fold increase in tumor retention with a corresponding improvement in most T/NT ratios over 72h. Conclusion: CC endolysosomal trapping provides a pathway to increase the efficacy and clinical potential of low molecular weight, receptor-targeted agents.